Benny Lava schreef op 3 april 2016 10:46:
Fase 1 studies met enkele berichtgevingen dit jaar. Het wordt denk ik pas spannend met fase 2 studie uitslagen, indien deze goed zijn natuurlijk.
'Official Title: A Phase I Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70
...
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date:
June 2016 (Final data collection date for primary outcome measure)'
www.clinicaltrials.gov/ct2/show/NCT01...About ARGX-113 Phase 1 study
'The Phase 1 study, where 20 healthy volunteers were treated with escalating doses of ARGX-113, is a double-blind, placebo-controlled study. The objective is to evaluate the safety and tolerability of ARGX-113 and to identify a potential dose for future Phase 2 studies. The topline results from the complete Phase 1 study are expected by
mid 2016'
ARGX-111
'Official Title: A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer Over-expressing the c-Met Protein.
...
Estimated Study Completion Date:
April 2016'
www.clinicaltrials.gov/ct2/show/NCT02...